Role of pegylated liposomal doxorubicin in ovarian cancer Review uri icon

Overview

MeSH Major

  • Antibiotics, Antineoplastic
  • Antineoplastic Combined Chemotherapy Protocols
  • Doxorubicin
  • Ovarian Neoplasms

abstract

  • Based on survival and toxicity advantages and a once-monthly administration schedule, pegylated liposomal doxorubicin is the first-choice nonplatinum agent for relapsed ovarian cancer. Pegylated liposomal doxorubicin may also have clinical application in combination regimens for platinum-sensitive ovarian cancer, as consolidation/maintenance therapy for ovarian cancer, as a component of first-line therapy for ovarian cancer, and in the treatment of other gynecologic malignancies. Future clinical trials will further define and maximize the role of pegylated liposomal doxorubicin in the treatment of ovarian cancer and other gynecologic malignancies.

publication date

  • January 2005

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.ygyno.2004.09.046

PubMed ID

  • 15589573

Additional Document Info

start page

  • 10

end page

  • 8

volume

  • 96

number

  • 1